Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus SODIUM PHOSPHATE P 32.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus SODIUM PHOSPHATE P 32.
CIS-MDP vs SODIUM PHOSPHATE P 32
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
Sodium phosphate P 32 is a radioactive isotope that emits beta particles, causing ionization and subsequent cell death, particularly in rapidly dividing cells. It is incorporated into DNA and RNA, concentrating in tissues with high metabolic activity such as bone marrow and neoplastic cells.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
Intravenous administration: 1.5 mCi (55.5 MBq) per 70 kg body weight, single dose. For polycythemia vera, oral dose: 3-5 mCi (111-185 MBq) as a single dose. Frequency is one-time or as needed based on response.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Terminal elimination half-life: 14.3 days (range 13-16 days). Clinically relevant for bone marrow suppression monitoring; cumulative effect over multiple doses.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Renal: ~40% within 24 hours via glomerular filtration; Fecal: ~60% over 1-2 weeks as unabsorbed or secreted into bile. Total elimination approaches 100% after 2 weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical